IP3R-Presenilin Interaction: Calcium Dysregulation in AD

About the Research Project
Program
Award Type
Standard
Award Amount
$400,000
Active Dates
April 01, 2008 - March 31, 2011
Grant ID
A2008137
Goals
This study is designed to test how presenilin interacts with calcium signaling proteins, resulting in changes to the presenilin function. The study will also examine how altered calcium signaling in turn affects other cell functions. These studies should provide new insights into the molecular mechanisms of AD and into the development of novel targets for therapeutic interventions.
Summary
Alzheimer’s disease (AD) is a common form of dementia involving slowly developing degeneration of neurons in the brain. The causes of AD are still not clear, but mutations in some proteins that result in early-onset cases of the disease provide clues. One of these proteins, presenilin, causes the amount of calcium in cells to be abnormally regulated. Because calcium regulates many brain functions, this abnormality may be a key part of the disease. We have discovered a mechanism whereby mutant forms of presenilin that cause AD alter the function of an important protein that regulates calcium signals in cells. Calcium in cells is precisely regulated, because it is toxic if its concentration is too high. Chronic abnormal calcium regulation as a result of mutations in presenilin may therefore cause cellular toxicity that leads to cell death. We plan to study how presenilin interacts with this important calcium signaling protein to alter its function, and how altered calcium signaling in turn affects cell functions. These studies should provide new insights into the molecular mechanisms of AD and into the development of novel targets for therapeutic interventions.
Progress Updates
Changes to the presenilin gene can cause familial Alzheimer’s disease (FAD), an early-onset form of Alzheimer’s disease (AD). Dr. Kevin Foskett and collaborators discovered that mutant presenilin proteins can interact with and stimulate the activity of an important protein that regulates calcium signals in cells, called InsP3R. This InsP3R stimulation results in abnormally exaggerated calcium signals in cells that, in turn, stimulates beta-amyloid protein processing, an important feature for progression to AD. These signals also enhance the production of toxic oxygen radicals, a feature of both AD and aging. In addition, Dr. Foskett showed that the effects of mutant presenilin proteins on calcium signaling mirrored what was previously known about FAD genetics. These effects were demonstrated both in cells derived from individuals with FAD and in brain neurons from mice that express the human mutant presenilin. Thus, Dr. Foskett’s discoveries provide new insights into what causes Alzheimer’s disease and could lead to the development of new targets for future treatments.
Grants
Related Grants
Alzheimer's Disease Research
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022
Principal Investigator
Hyunjun Yang, PhD
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022

Principal Investigator
Hyunjun Yang, PhD
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD